🔍 Observations
Topline
- Revenue surged 33.1% YoY to ₹1,33,937L in FY26, accelerating sharply from the prior base of ₹1,00,668L — sustained by pharma API custom synthesis demand.
- Q4 FY26 revenue hit ₹43,275L, up 40.3% YoY vs Q4 FY25’s ₹30,848L — strongest quarter of the year, suggesting momentum is building, not peaking.
- Other income jumped 145.6% YoY to ₹4,159L, driven by unrealised FX gains and FD interest — meaningful but non-recurring contributor to total income.
Bottomline
- PAT nearly doubled: ₹35,637L in FY26 vs ₹16,042L in FY25 — a 122.2% YoY leap, far outpacing revenue growth, signalling operating leverage kicking in.
- Q4 FY26 PAT of ₹13,428L is 114.1% above Q4 FY25’s ₹6,272L — quarterly profitability compounding at an exceptional rate.
- Basic EPS grew from ₹19.81 to ₹43.51 (+119.6% YoY) on a near-static share count, confirming profit growth is organic, not dilution-driven.
Margins
- EBITDA margin expanded from 24.93% to 38.97% — a 1,404 bps improvement, exceptional for a manufacturing business.
- PAT margin widened from 15.94% to 26.61% — cost structure scaling better than revenue, driven by operating leverage on fixed overheads.
- Employee cost as % of revenue increased (₹11,758L vs ₹8,366L, +40.6% YoY) — talent investment tracking revenue growth, a manageable trade-off given margin expansion.
Growth Trajectory
- Revenue CAGR implied over FY25–26 is 33.1%; PAT CAGR is 122.2% — bottomline is scaling at 3.7x the topline rate, a hallmark of high-operating-leverage specialty chemical businesses.
- CWIP more than doubled to ₹33,232L — signals significant capacity additions underway; revenue growth runway is backed by hard assets, not just demand.
- Sequential Q3→Q4 FY26 revenue growth of 10.1% and PAT growth of 26.4% confirm the trajectory is accelerating within the fiscal year itself.
🧮 Profit & Loss Statement
🧮 Balance Sheet
🧮 Cash Flows Statement
🟢 Green Flags
- PAT up 122% YoY while diluted share count barely moved — pure earnings power, no equity dilution noise.
- EBITDA margin at 38.97% is elite for a specialty chemicals manufacturer — pricing power and product mix are working.
- Debt-light balance sheet: Total borrowings of ₹2,649L against equity of ₹1,71,075L — debt-to-equity of ~0.015x; financial risk is negligible.
- Operating cash flow of ₹29,217L — covers CapEx of ₹32,798L at ~89%, with cash reserves bridging the gap comfortably.
- Cash on hand of ₹21,555L with additional FDs — liquidity position is strong; no refinancing risk in sight.
- CWIP of ₹33,232L signals a committed capacity expansion pipeline, supporting forward revenue growth visibility.
- Q4 FY26 sequential improvement in both revenue (+10.1%) and PAT (+26.4%) confirms no post-peak normalization — momentum intact.
🔴 Red Flags
- Trade receivables up 24.8% YoY (₹29,049L → ₹36,256L) vs. revenue growth of 33.1% — receivables days need monitoring; ₹5,549L cash absorbed from operations.
- Other income of ₹4,159L includes ₹1,602L unrealised FX gains — strip these out and reported PBT/PAT is optically flattered.
- Inventory build of ₹5,138L in operating cash flow — rising inventory in tandem with receivables is a dual working capital drag.
- Employee costs +40.6% YoY — faster than revenue in Q4 FY26 (₹3,329L vs ₹2,330L); talent cost inflation could compress margins if volumes disappoint.
- Goodwill jumped to ₹10,434L from ₹5,680L — acquisition-related; impairment risk exists if acquired entity underperforms.
- Short-term borrowings grew to ₹2,649L from ₹818L — modest in absolute terms, but a 223.7% increase deserves a watch for trend continuation.
- Free cash flow negative: OCF ₹29,217L less CapEx ₹32,798L = –₹3,581L — company is in investment mode; FCF generation expected only post-capacity stabilization.
📊 Balance Sheet Analysis
- Asset quality is strong: PPE of ₹58,280L + CWIP of ₹33,232L represent productive and pipeline assets; total non-current assets grew 45.5% YoY — capacity-building, not asset inflation.
- Equity-heavy capital structure: Equity at ₹1,71,075L vs total liabilities of ₹27,321L gives a debt-to-asset ratio of 13.8% — pristine leverage profile.
- Liquidity comfortable: Current ratio = ₹88,127L / ₹23,081L = 3.82x — current assets nearly 4x current liabilities; short-term solvency is not a concern.
- NCI jump to ₹5,719L from ₹1,045L signals a subsidiary consolidation or acquisition — warrants transparency on subsidiary profitability contribution.
💰 Cash Flow Analysis
- OCF of ₹29,217L vs FY25’s ₹11,834L — 146.9% YoY improvement; operating cash generation is scaling proportionally with profits, validating earnings quality.
- Investing outflow of ₹26,594L driven by ₹32,798L CapEx — growth-oriented deployment; company is investing ahead of revenue, not chasing it.
- Financing inflows of ₹410L are near-neutral — no meaningful debt raise or equity issuance; FY25’s ₹26,112L inflow was IPO-driven, now normalised.
- Net cash position improved by ₹3,033L to ₹21,555L — despite heavy CapEx, the business self-funds operations and retains cash surplus.
💡 Investment Outlook
Acutaas Chemicals delivered an exceptional FY26 — revenue at ₹1,339 Cr, PAT at ₹356 Cr, and EBITDA margins near 39% put it firmly in the high-quality specialty chemicals category.
The debt-free balance sheet, accelerating quarterly trajectory, and ₹33,232L CWIP pipeline provide credible forward growth visibility.
Key monitorables: working capital cycle discipline (receivables + inventory), post-expansion margin sustainability, and disclosure quality on the acquired subsidiary driving goodwill and NCI growth.
Disclaimer: This post features ChartAlert-AI-generated financial content which may contain inaccuracies or errors. This commentary is strictly for informational purposes and does not constitute a recommendation to buy or sell any security. Investors are responsible for performing their own due diligence; always consult with a licensed financial advisor before making investment decisions.
Beyond the Price Action: Fundamental Analysis is Coming to ChartAlert
ChartAlert is evolving into integrated research with a future update that will embed fundamental data into your workflow. Alongside technical analysis, the new release will allow access to financial spreadsheets, quarterly results review, earnings call transcripts, and valuation tools, connecting price action with corporate performance for smarter, data‑driven decisions.